The University of Chicago Header Logo

Connection

Peter O'Donnell to Prostatic Neoplasms, Castration-Resistant

Back to Details
This is a "connection" page, showing publications Peter O'Donnell has written about Prostatic Neoplasms, Castration-Resistant.
Peter O'Donnell
Connection Strength
0.296
Prostatic Neoplasms, Castration-Resistant
  1. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
    View in: PubMed
    Score: 0.191
  2. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
    View in: PubMed
    Score: 0.105
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.